H.R. 9393 · 119th Congress · Health
Lower Costs, More Transparency Act of 2026
Increases transparency and reduces costs in health care pricing and coverage. AI-read
- IntroducedJun 23, 2026 Done
- CommitteeReferred to 3 committees Current stage
- House floorNot yet Not reached yet
- Senate floorNot yet Not reached yet
- Chambers agreeNot yet Not reached yet
- PresidentNot yet Not reached yet
What it does
The Congressional Research Service hasn’t published a summary of this bill. Read the full text on Congress.gov.Who lobbies on it
25 organizations, more than 99% of House bills · 51 filings · Q2 2026–Q3 2026One square per quarter since introduction, oldest left. Filled = named it that quarter.
-
American Medical Association
2 of 2 quarters
“…H.R.9393 - Lower Costs, More Transparency Act of 2026, all provisions H.R.9396 - Prior Authorization Accountability Act, all provisions S. 380 - Rural Obstetrics Readiness Act, all provisions S.1390 - Physician Led and Rural Access to Quality Care Act, all provisions S.1419 - Youth Sports Facilities Act of 2025, all…”
$17.6M lobbying spend in 2026 to date, all issuesQ3 2026 filing
-
American Hospital Association
2 of 2 quarters
“…H.R. 9393, Lower Costs More Transparency Act of 2026, all provisions; S.4252, WIPP Economic Assistance Assurance Act of 2026, all provisions; S.3364, Fast Track Healthcare Apprenticeships Act, all provisions; H.R. 8726, the Protecting Authority and Restoring Tools Necessary for Enforcement by Regulatory States Act of…”
$14.4M lobbying spend in 2026 to date, all issuesQ3 2026 filing
-
America's Health Insurance Plans Inc (ahip)
2 of 2 quarters
“…H.R. 9393 - Lower Costs, More Transparency Act - Rep. Guthrie, Brett - Healthcare price transparency H.R. 9645 - Health Care Price Certainty for All Americans Act - Rep. Smith, Jason - Price transparency requirements H.R. 10024 - Health Insurance Transparency for Patients Act - Rep. Hinson, Ashley - Price transparency…”
$11.3M lobbying spend in 2026 to date, all issuesQ3 2026 filing
22 more organizations, every filingPROUpgrade
Organizations that named H.R. 9393 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. “Gave to” means the organization’s PAC gave to the member’s campaign in the 2025–26 cycle, net of refunds; it doesn’t mean the money was about this bill. Organizations may lobby for, against, or to change a bill; filings don’t say which. Source: Senate lobbying disclosures (LD-2) from lda.gov; PAC gifts from FEC filings; quotes are word for word from the “specific lobbying issues” field; where a filing lists many bills, the quote starts where it names this one.
Actions
8 actions · newest first- Jul 21, 2026Ordered to be Reported in the Nature of a Substitute by the Yeas and Nays: 45 - 0.
- Jul 21, 2026Committee Consideration and Mark-up Session Held
- Jul 20, 2026Committee Consideration and Mark-up Session Held
- Jun 25, 2026Forwarded by Subcommittee to Full Committee by Voice Vote.
Show all 8 actionsShow fewer
- Jun 25, 2026Subcommittee Consideration and Mark-up Session Held
- Jun 23, 2026Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Education and Workforce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Jun 23, 2026Referred to the Subcommittee on Health.
- Jun 23, 2026Introduced in House
What members said about it
-
Today, the House Energy and Commerce Committee advanced two bills introduced by Congressman Bob Latta (OH-5) to combat the rising synthetic opioid deaths: The Strengthening Tools to Outlaw Poisonous (STOP) Nitazenes Act and Tyler’s Law.
“Today’s advancement of the STOP Nitazenes Act and Tyler’s Law out of committee is an important step forward in our efforts to save lives and confront the devastating impact of synthetic opioids in communities across the country. These bills will help ensure hospitals and health officials have the tools, data, and…”
-
McClellan Bill to Increase Data Transparency for Medicare Advantage Supplemental Benefits Advances
Today, Congresswoman Jennifer McClellan (VA-04)’s bill, H.R. 5243, unanimously advanced out of the Energy & Commerce Committee to the House floor for a vote as part of H.R. 9393, the Lower Costs, More Transparency Act of 2026.
“Seniors deserve the most up-to-date and accurate information about the benefits and providers available to them when making health care coverage decisions. Yet a lack of data around Medicare Advantage supplemental benefit plans leads too many people to make decisions that don’t fully meet their needs.”